Last Updated : October 16, 2023
Details
Generic Name:
daratumumab
Project Status:
Not filed
Therapeutic Area:
Multiple myeloma, eligible for autologous stem cell transplant
Manufacturer:
Janssen Canada Inc.
Brand Name:
Darzalex
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Submission Type:
Non Submission
Indications:
In combination with bortezomib, thalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023